Therapeutic potential of adenosine kinase inhibitors

Expert Opinion on Investigational Drugs

Volumn 9, Issue 3, 2000, Pages 551-564

  Kowaluk, E A ^a   Jarvis, M F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

5' Amino 5' deoxyadenosine; 5' Deoxy 5 iodotubercidin; 5 Iodotubercidin; A 134974; Adenosine; Adenosine kinase; Analgesia; Cerebral ischaemia; Epilepsy; GP3269; GP683; Inflammation; Seizures

Indexed keywords

4 ANILINO 5 PHENYLPYRROLO[2,3 D]PYRIMIDINE 7 (5 DEOXYRIBOSIDE); A 134974; ADENOSINE; ADENOSINE KINASE INHIBITOR; AKI 2; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ARISTEROMYCIN; DIZOCILPINE; G PROTEIN COUPLED RECEPTOR; GP 3269; GP 515; GP 947; NEUROTRANSMITTER; TUBERCIDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN ISCHEMIA; CELL MEMBRANE TRANSPORT; CLINICAL TRIAL; DRUG SPECIFICITY; ENZYME RELEASE; EPILEPSY; HUMAN; INFLAMMATION; INJURY; ION TRANSPORT; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; POLARIZATION; REVIEW; STRESS; STRUCTURE ACTIVITY RELATION;

EID: 0033995205     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.3.551     Document Type: Review

References (103)